$HYEX
HEALTHY EXTRACTS INC. Stock $hyex

$hyex Overview Financials Valuation SEC Filings Company Website

2023 Q1 Form 10-K Financial Statement

#000109690623000699 Filed on March 31, 2023

Income Statement

Concept	2023 Q1	2022 Q4	2022
Revenue	$614.9K	$818.6K	$2.251M
YoY Change	32.71%	21.89%	53.6%
Cost Of Revenue	$337.1K	$401.1K	$880.0K
YoY Change	143.08%	101.86%	154.2%
Gross Profit	$277.8K	$417.5K	$1.372M
YoY Change	-14.43%	-11.71%	22.5%
Gross Profit Margin	45.18%	51.0%	60.92%
Selling, General & Admin	$683.0K	$538.8K	$2.283M
YoY Change	84.42%	-24.16%	-11.65%
% of Gross Profit	245.83%	129.04%	166.47%
Research & Development
YoY Change
% of Gross Profit
Depreciation & Amortization	$550.00	$550.00	$880.00
YoY Change		-56.69%	-82.75%
% of Gross Profit	0.2%	0.13%	0.06%
Operating Expenses	$683.0K	$538.8K	$2.283M
YoY Change	84.42%	-24.16%	-11.65%
Operating Profit	-$405.2K	-$121.3K	-$911.6K
YoY Change	787.6%	-48.94%	-37.76%
Interest Expense	-$174.0K	$240.8K	-$74.17K
YoY Change	-478.03%	-79.92%	-46.17%
% of Operating Profit
Other Income/Expense, Net	-$174.0K		-$71.53K
YoY Change	-457.49%		-26.97%
Pretax Income	-$579.2K	$43.42K	-$983.1K
YoY Change	-19341.2%	-91.91%	-50.53%
Income Tax	$0.00		$0.00
% Of Pretax Income
Net Earnings	-$579.2K	$43.42K	-$983.1K
YoY Change	-19341.1%	-91.91%	-50.53%
Net Earnings / Revenue	-94.18%	5.3%	-43.67%
Basic Earnings Per Share
Diluted Earnings Per Share	$0.00	$0.00	$0.00
COMMON SHARES
Basic Shares Outstanding	345.2M shares
Diluted Shares Outstanding

Balance Sheet

Concept	2023 Q1	2022 Q4	2022
SHORT-TERM ASSETS
Cash & Short-Term Investments	$213.2K	$65.65K	$65.65K
YoY Change	131.01%	-70.44%	-70.44%
Cash & Equivalents	$213.2K	$65.65K
Short-Term Investments
Other Short-Term Assets		$0.00	$0.00
YoY Change
Inventory	$1.654M	$1.819M	$1.819M
Prepaid Expenses
Receivables	$135.4K	$105.8K	$105.8K
Other Receivables	$0.00	$0.00	$0.00
Total Short-Term Assets	$2.003M	$1.991M	$1.991M
YoY Change	-9.37%	-13.95%	-13.95%
LONG-TERM ASSETS
Property, Plant & Equipment	$4.950K	$5.500K	$5.500K
YoY Change	-30.77%	428.85%	428.85%
Goodwill	$193.3K	$193.3K
YoY Change		0.0%
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets	$102.5K	$69.90K	$69.90K
YoY Change	506.99%
Total Long-Term Assets	$822.6K	$790.5K	$790.6K
YoY Change	11.29%	10.38%	10.38%
TOTAL ASSETS
Total Short-Term Assets	$2.003M	$1.991M	$1.991M
Total Long-Term Assets	$822.6K	$790.5K	$790.6K
Total Assets	$2.825M	$2.781M	$2.781M
YoY Change	-4.2%	-8.2%	-8.2%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$114.5K	$91.32K	$91.32K
YoY Change	8.6%	145.03%	145.02%
Accrued Expenses	$85.87K	$94.55K	$115.9K
YoY Change	215.24%	59.55%	34.14%
Deferred Revenue
YoY Change
Short-Term Debt	$1.084M	$593.5K	$593.5K
YoY Change	203.1%	73.23%	73.23%
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$1.510M	$902.8K	$902.8K
YoY Change	199.75%	61.55%	61.55%
LONG-TERM LIABILITIES
Long-Term Debt	$0.00	$0.00	$0.00
YoY Change
Other Long-Term Liabilities			$0.00
YoY Change
Total Long-Term Liabilities	$0.00	$0.00	$0.00
YoY Change
TOTAL LIABILITIES
Total Short-Term Liabilities	$1.510M	$902.8K	$902.8K
Total Long-Term Liabilities	$0.00	$0.00	$0.00
Total Liabilities	$1.510M	$902.8K	$902.8K
YoY Change	199.75%	61.55%	61.55%
SHAREHOLDERS EQUITY
Retained Earnings	-$16.51M	-$15.93M
YoY Change		6.58%
Common Stock	$345.5K	$345.2K
YoY Change		2.01%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$1.315M	$1.878M	$1.878M
YoY Change
Total Liabilities & Shareholders Equity	$2.825M	$2.781M	$2.781M
YoY Change	-4.2%	-8.2%	-8.2%

Cashflow Statement

Concept	2023 Q1	2022 Q4	2022
OPERATING ACTIVITIES
Net Income	-$579.2K	$43.42K	-$983.1K
YoY Change	-19341.1%	-91.91%	-50.53%
Depreciation, Depletion And Amortization	$550.00	$550.00	$880.00
YoY Change		-56.69%	-82.75%
Cash From Operating Activities	-$310.3K	-$93.94K	-$335.0K
YoY Change	186.19%	-329.79%	-62.84%
INVESTING ACTIVITIES
Capital Expenditures	$0.00	$0.00	$7.987K
YoY Change	-100.0%	-100.0%
Acquisitions
YoY Change
Other Investing Activities	$0.00	$0.00	$0.00
YoY Change
Cash From Investing Activities	$0.00	$0.00	-$7.987K
YoY Change	-100.0%	-100.0%	-91.68%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net			-$11.39K
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	$457.8K	85.71K	$186.5K
YoY Change	-3511.42%	11.02%	-83.92%
NET CHANGE
Cash From Operating Activities	-$310.3K	-93.94K	-$335.0K
Cash From Investing Activities	$0.00	0.000	-$7.987K
Cash From Financing Activities	$457.8K	85.71K	$186.5K
Net Change In Cash	$147.6K	-8.230K	-$156.4K
YoY Change	-213.66%	-107.69%	-196.04%
FREE CASH FLOW
Cash From Operating Activities	-$310.3K	-$93.94K	-$335.0K
Capital Expenditures	$0.00	$0.00	$7.987K
Free Cash Flow	-$310.3K	-$93.94K	-$343.0K
YoY Change	208.96%	-280.69%	-61.95%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2022	dei	Document Type DocumentType	10-K
CY2022	dei	Document Annual Report DocumentAnnualReport	true
CY2022	dei	Document Period End Date DocumentPeriodEndDate	2022-12-31
CY2022	dei	Document Transition Report DocumentTransitionReport	false
CY2022	dei	Entity File Number EntityFileNumber	000-55572
CY2022	dei	Entity Registrant Name EntityRegistrantName	Healthy Extracts, Inc.
CY2022	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	NV
CY2022	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	47-2594704
CY2022	dei	Entity Address Address Line1 EntityAddressAddressLine1	7375 Commercial Way
CY2022	dei	Entity Address Address Line2 EntityAddressAddressLine2	Suite 125
CY2022	dei	Entity Address City Or Town EntityAddressCityOrTown	Henderson
CY2022	dei	Entity Address State Or Province EntityAddressStateOrProvince	NV
CY2022	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	89011
CY2022	dei	City Area Code CityAreaCode	720
CY2022	dei	Local Phone Number LocalPhoneNumber	463-1004
CY2022	dei	Entity Well Known Seasoned Issuer EntityWellKnownSeasonedIssuer	No
CY2022	dei	Entity Voluntary Filers EntityVoluntaryFilers	No
CY2022	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2022	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
CY2022	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
CY2022	dei	Entity Small Business EntitySmallBusiness	true
CY2021Q4	us-gaap	Interest Payable Current InterestPayableCurrent	13050	usd
CY2022Q4	fil	Accrued Interest Payable Related Party AccruedInterestPayableRelatedParty	0	usd
CY2022	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
CY2022	dei	Document Fin Stmt Error Correction Flag DocumentFinStmtErrorCorrectionFlag	false
CY2022	dei	Entity Shell Company EntityShellCompany	false
CY2022Q2	dei	Entity Public Float EntityPublicFloat	9911517	usd
CY2023Q1	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	345172442	shares
CY2022	dei	Auditor Name AuditorName	BF Borgers CPA PC
CY2022	dei	Auditor Firm AuditorFirmId	5041
CY2022	dei	Auditor Location AuditorLocation	Lakewood, CO
CY2022Q4	us-gaap	Cash Cash	65651	usd
CY2021Q4	us-gaap	Cash Cash	222098	usd
CY2022Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	105794	usd
CY2021Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	133340	usd
CY2022Q4	us-gaap	Inventory Net InventoryNet	1819128	usd
CY2021Q4	us-gaap	Inventory Net InventoryNet	1957966	usd
CY2022Q4	us-gaap	Assets Current AssetsCurrent	1990572	usd
CY2021Q4	us-gaap	Assets Current AssetsCurrent	2313404	usd
CY2022Q4	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	44709	usd
CY2021Q4	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	45474	usd
CY2022Q4	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	5501	usd
CY2021Q4	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	1035	usd
CY2022Q4	us-gaap	Finite Lived Patents Gross FiniteLivedPatentsGross	521881	usd
CY2021Q4	us-gaap	Finite Lived Patents Gross FiniteLivedPatentsGross	521881	usd
CY2022Q4	us-gaap	Deposits Assets DepositsAssets	16890	usd
CY2021Q4	us-gaap	Deposits Assets DepositsAssets	0	usd
CY2022Q4	us-gaap	Prepaid Expense Noncurrent PrepaidExpenseNoncurrent	53015	usd
CY2021Q4	us-gaap	Prepaid Expense Noncurrent PrepaidExpenseNoncurrent	0	usd
CY2022Q4	us-gaap	Goodwill Goodwill	193260	usd
CY2021Q4	us-gaap	Goodwill Goodwill	193260	usd
CY2022Q4	us-gaap	Other Assets OtherAssets	790546	usd
CY2021Q4	us-gaap	Other Assets OtherAssets	716175	usd
CY2022Q4	us-gaap	Assets Assets	2781118	usd
CY2021Q4	us-gaap	Assets Assets	3029579	usd
CY2022Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	91316	usd
CY2021Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	37267	usd
CY2022Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	94554	usd
CY2021Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	59264	usd
CY2022Q4	us-gaap	Notes Payable Current NotesPayableCurrent	275370	usd
CY2021Q4	us-gaap	Notes Payable Current NotesPayableCurrent	0	usd
CY2022Q4	fil	Notes Payable Related Party NotesPayableRelatedParty	866	usd
CY2021Q4	fil	Notes Payable Related Party NotesPayableRelatedParty	170866	usd
CY2022Q4	us-gaap	Convertible Notes Payable Current ConvertibleNotesPayableCurrent	317284	usd
CY2021Q4	us-gaap	Convertible Notes Payable Current ConvertibleNotesPayableCurrent	171750	usd
CY2022Q4	fil	Convertible Debt Related Party Net Of Discount ConvertibleDebtRelatedPartyNetOfDiscount	0	usd
CY2021Q4	fil	Convertible Debt Related Party Net Of Discount ConvertibleDebtRelatedPartyNetOfDiscount	0	usd
CY2022Q4	us-gaap	Interest Payable Current InterestPayableCurrent	21387	usd
CY2021Q4	fil	Accrued Interest Payable Related Party AccruedInterestPayableRelatedParty	14118	usd
CY2022Q4	us-gaap	Derivative Liabilities DerivativeLiabilities	102011	usd
CY2021Q4	us-gaap	Derivative Liabilities DerivativeLiabilities	92527	usd
CY2022Q4	us-gaap	Liabilities Current LiabilitiesCurrent	902788	usd
CY2021Q4	us-gaap	Liabilities Current LiabilitiesCurrent	558841	usd
CY2022Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2021Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2022Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	75000000	shares
CY2021Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	75000000	shares
CY2022Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2021Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2022Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2021Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2022Q4	us-gaap	Preferred Stock Value PreferredStockValue	0	usd
CY2021Q4	us-gaap	Preferred Stock Value PreferredStockValue	0	usd
CY2022Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2021Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2022Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	2500000000	shares
CY2021Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	2500000000	shares
CY2022Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	345172442	shares
CY2022Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	345172442	shares
CY2021Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	338384171	shares
CY2021Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	338384171	shares
CY2022Q4	us-gaap	Common Stock Value CommonStockValue	345172	usd
CY2021Q4	us-gaap	Common Stock Value CommonStockValue	338384	usd
CY2022Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	17459899	usd
CY2021Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	17075974	usd
CY2022Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-15926742	usd
CY2021Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-14943620	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	1878330	usd
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	2470738	usd
CY2022Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	2781118	usd
CY2021Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	3029579	usd
CY2022	us-gaap	Sales Type Lease Revenue SalesTypeLeaseRevenue	2251469	usd
CY2021	us-gaap	Sales Type Lease Revenue SalesTypeLeaseRevenue	1676598	usd
CY2022	us-gaap	Revenues Revenues	2251469	usd
CY2021	us-gaap	Revenues Revenues	1676598	usd
CY2022	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	783141	usd
CY2021	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	556972	usd
CY2022	us-gaap	Inventory Write Down InventoryWriteDown	96811	usd
CY2021	us-gaap	Inventory Write Down InventoryWriteDown	424548	usd
CY2022	us-gaap	Cost Of Revenue CostOfRevenue	879951	usd
CY2021	us-gaap	Cost Of Revenue CostOfRevenue	981520	usd
CY2022	us-gaap	Gross Profit GrossProfit	1371517	usd
CY2021	us-gaap	Gross Profit GrossProfit	695078	usd
CY2022	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	2283107	usd
CY2021	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	2584256	usd
CY2022	us-gaap	Operating Expenses OperatingExpenses	2283107	usd
CY2021	us-gaap	Operating Expenses OperatingExpenses	2584256	usd
CY2022	us-gaap	Interest Income Expense Net InterestIncomeExpenseNet	-64690	usd
CY2021	us-gaap	Interest Income Expense Net InterestIncomeExpenseNet	-52453	usd
CY2022	us-gaap	Unrealized Gain Loss On Derivatives UnrealizedGainLossOnDerivatives	-9484	usd
CY2021	us-gaap	Unrealized Gain Loss On Derivatives UnrealizedGainLossOnDerivatives	-85325	usd
CY2022	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	0	usd
CY2021	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	0	usd
CY2022	fil	Sba Loan Forgiveness SbaLoanForgiveness	0	usd
CY2021	fil	Sba Loan Forgiveness SbaLoanForgiveness	-39833	usd
CY2022	us-gaap	Gain Loss On Sale Of Other Assets GainLossOnSaleOfOtherAssets	2643	usd
CY2021	us-gaap	Gain Loss On Sale Of Other Assets GainLossOnSaleOfOtherAssets	0	usd
CY2022	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-71531	usd
CY2021	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-97945	usd
CY2022	us-gaap	Profit Loss ProfitLoss	-983121	usd
CY2021	us-gaap	Profit Loss ProfitLoss	-1987122	usd
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-983121	usd
CY2021	us-gaap	Net Income Loss NetIncomeLoss	-1987122	usd
CY2022	fil	Loss Per Share Basic And Diluted LossPerShareBasicAndDiluted	-0.00
CY2021	fil	Loss Per Share Basic And Diluted LossPerShareBasicAndDiluted	-0.01
CY2022	fil	Weighted Average Number Of Shares Outstanding Basic And Diluted WeightedAverageNumberOfSharesOutstandingBasicAndDiluted	342514810	shares
CY2021	fil	Weighted Average Number Of Shares Outstanding Basic And Diluted WeightedAverageNumberOfSharesOutstandingBasicAndDiluted	319209932	shares
CY2020Q4	us-gaap	Stockholders Equity StockholdersEquity	2853826	usd
CY2021	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	45000	usd
CY2021	fil	Stock Issued During Period Value New Issues2 StockIssuedDuringPeriodValueNewIssues2	15000	usd
CY2021	fil	Stock Issued During Period Value New Issues3 StockIssuedDuringPeriodValueNewIssues3	165000	usd
CY2021	fil	Stock Issued During Period Value New Issues4 StockIssuedDuringPeriodValueNewIssues4	0	usd
CY2021	us-gaap	Debt Conversion Converted Instrument Amount1 DebtConversionConvertedInstrumentAmount1	86400	usd
CY2021	us-gaap	Stock Issued During Period Value Issued For Services StockIssuedDuringPeriodValueIssuedForServices	51480	usd
CY2021	fil	Stock Issued During Period Value Issued For Services2 StockIssuedDuringPeriodValueIssuedForServices2	144000	usd
CY2021	fil	Stock Issued During Period Value Issued For Services3 StockIssuedDuringPeriodValueIssuedForServices3	60000	usd
CY2021	fil	Stock Issued During Period Value Issued For Services4 StockIssuedDuringPeriodValueIssuedForServices4	91956	usd
CY2021	fil	Debt Conversion Converted Instrument Amount12 DebtConversionConvertedInstrumentAmount12	60000	usd
CY2021	fil	Stock Issued During Period Value Issued For Services5 StockIssuedDuringPeriodValueIssuedForServices5	175000	usd
CY2021	fil	Issuance Of Common Stock For Cash5 IssuanceOfCommonStockForCash5	100000	usd
CY2021	fil	Debt Conversion Converted Instrument Amount13 DebtConversionConvertedInstrumentAmount13	610199	usd
CY2021	us-gaap	Net Income Loss NetIncomeLoss	-1987122	usd
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	2470738	usd
CY2022	fil	Cancelation Of Common Stock For Debt CancelationOfCommonStockForDebt	-10013	usd
CY2022	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	25396	usd
CY2022	fil	Cancelation Of Common Stock For Debt1 CancelationOfCommonStockForDebt1	-43800	usd
CY2022	us-gaap	Stock Issued During Period Value Issued For Services StockIssuedDuringPeriodValueIssuedForServices	64000	usd
CY2022	fil	Stock Issued During Period Value Issued For Services2 StockIssuedDuringPeriodValueIssuedForServices2	57100	usd
CY2022	fil	Stock Issued During Period Value Issued For Services3 StockIssuedDuringPeriodValueIssuedForServices3	264000	usd
CY2022	fil	Issuance Of Common Stock Note Conversion IssuanceOfCommonStockNoteConversion	17031	usd
CY2022	fil	Stock Issued During Period Value Issued For Services4 StockIssuedDuringPeriodValueIssuedForServices4	17000	usd
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-983121	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	1878330	usd
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-983121	usd
CY2021	us-gaap	Net Income Loss NetIncomeLoss	-1987122	usd
CY2022	fil	Depreciation And Amortization1 DepreciationAndAmortization1	878	usd
CY2021	fil	Depreciation And Amortization1 DepreciationAndAmortization1	5100	usd
CY2022	us-gaap	Issuance Of Stock And Warrants For Services Or Claims IssuanceOfStockAndWarrantsForServicesOrClaims	402100	usd
CY2021	us-gaap	Issuance Of Stock And Warrants For Services Or Claims IssuanceOfStockAndWarrantsForServicesOrClaims	608836	usd
CY2022	us-gaap	Share Based Compensation ShareBasedCompensation	0	usd
CY2021	us-gaap	Share Based Compensation ShareBasedCompensation	0	usd
CY2022	us-gaap	Increase Decrease In Derivative Liabilities IncreaseDecreaseInDerivativeLiabilities	9484	usd
CY2021	us-gaap	Increase Decrease In Derivative Liabilities IncreaseDecreaseInDerivativeLiabilities	85325	usd
CY2022	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	0	usd
CY2021	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	0	usd
CY2022	us-gaap	Gains Losses On Sales Of Assets GainsLossesOnSalesOfAssets	-2643	usd
CY2021	us-gaap	Gains Losses On Sales Of Assets GainsLossesOnSalesOfAssets	0	usd
CY2022	us-gaap	Goodwill And Intangible Asset Impairment GoodwillAndIntangibleAssetImpairment	0	usd
CY2021	us-gaap	Goodwill And Intangible Asset Impairment GoodwillAndIntangibleAssetImpairment	0	usd
CY2022	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-27547	usd
CY2021	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	120066	usd
CY2022	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	-138838	usd
CY2021	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	-459717	usd
CY2022	us-gaap	Increase Decrease In Accrued Interest Receivable Net IncreaseDecreaseInAccruedInterestReceivableNet	0	usd
CY2021	us-gaap	Increase Decrease In Accrued Interest Receivable Net IncreaseDecreaseInAccruedInterestReceivableNet	0	usd
CY2022	us-gaap	Increase Decrease In Deposits IncreaseDecreaseInDeposits	-16890	usd
CY2021	us-gaap	Increase Decrease In Deposits IncreaseDecreaseInDeposits	0	usd
CY2022	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	54048	usd
CY2021	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-27569	usd
CY2022	us-gaap	Increase Decrease In Accounts Payable Related Parties IncreaseDecreaseInAccountsPayableRelatedParties	0	usd
CY2021	us-gaap	Increase Decrease In Accounts Payable Related Parties IncreaseDecreaseInAccountsPayableRelatedParties	0	usd
CY2022	us-gaap	Increase Decrease In Employee Related Liabilities IncreaseDecreaseInEmployeeRelatedLiabilities	35291	usd
CY2021	us-gaap	Increase Decrease In Employee Related Liabilities IncreaseDecreaseInEmployeeRelatedLiabilities	50210	usd
CY2022	us-gaap	Increase Decrease In Interest Payable Net IncreaseDecreaseInInterestPayableNet	8337	usd
CY2021	us-gaap	Increase Decrease In Interest Payable Net IncreaseDecreaseInInterestPayableNet	10671	usd
CY2022	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	-14118	usd
CY2021	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	13600	usd
CY2022	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-334964	usd
CY2021	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-901298	usd
CY2022	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	7987	usd
CY2021	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	0	usd
CY2022	us-gaap	Proceeds From Sale Of Property Plant And Equipment ProceedsFromSaleOfPropertyPlantAndEquipment	0	usd
CY2021	us-gaap	Proceeds From Sale Of Property Plant And Equipment ProceedsFromSaleOfPropertyPlantAndEquipment	0	usd
CY2022	fil	Purchase Of Note Receivable PurchaseOfNoteReceivable	0	usd
CY2021	fil	Purchase Of Note Receivable PurchaseOfNoteReceivable	0	usd
CY2022	fil	Increase Decrease In Trademarks IncreaseDecreaseInTrademarks	0	usd
CY2021	fil	Increase Decrease In Trademarks IncreaseDecreaseInTrademarks	-96004	usd
CY2022	us-gaap	Repayment Of Notes Receivable From Related Parties RepaymentOfNotesReceivableFromRelatedParties	0	usd
CY2021	us-gaap	Repayment Of Notes Receivable From Related Parties RepaymentOfNotesReceivableFromRelatedParties	0	usd
CY2022	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-7987	usd
CY2021	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-96004	usd
CY2022	us-gaap	Business Combination Acquisition Related Costs BusinessCombinationAcquisitionRelatedCosts	0	usd
CY2021	us-gaap	Business Combination Acquisition Related Costs BusinessCombinationAcquisitionRelatedCosts	0	usd
CY2022	fil	Purchase Of Hyperion Op M PurchaseOfHyperionOpM	-53015	usd
CY2021	fil	Purchase Of Hyperion Op M PurchaseOfHyperionOpM	0	usd
CY2022	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	-11386	usd
CY2021	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	995199	usd
CY2022	us-gaap	Proceeds From Convertible Debt ProceedsFromConvertibleDebt	463630	usd
CY2021	us-gaap	Proceeds From Convertible Debt ProceedsFromConvertibleDebt	165000	usd
CY2022	us-gaap	Repayments Of Convertible Debt RepaymentsOfConvertibleDebt	318095	usd
CY2021	us-gaap	Repayments Of Convertible Debt RepaymentsOfConvertibleDebt	0	usd
CY2022	us-gaap	Proceeds From Notes Payable ProceedsFromNotesPayable	275370	usd
CY2021	us-gaap	Proceeds From Notes Payable ProceedsFromNotesPayable	0	usd
CY2022	fil	Proceeds From Issuance Of Notes Payable Related Party ProceedsFromIssuanceOfNotesPayableRelatedParty	0	usd
CY2021	fil	Proceeds From Issuance Of Notes Payable Related Party ProceedsFromIssuanceOfNotesPayableRelatedParty	0	usd
CY2022	us-gaap	Proceeds From Repayments Of Notes Payable ProceedsFromRepaymentsOfNotesPayable	-170000	usd
CY2021	us-gaap	Proceeds From Repayments Of Notes Payable ProceedsFromRepaymentsOfNotesPayable	0	usd
CY2022	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	186504	usd
CY2021	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	1160199	usd
CY2022	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-156447	usd
CY2021	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	162897	usd
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	222098	usd
CY2020Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	59201	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	65651	usd
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	222098	usd
CY2022	us-gaap	Use Of Estimates UseOfEstimates	<p style="font:11pt Times New Roman;margin:0;text-align:justify"><b><i>Use of Estimates</i></b></p> <p style="font:11pt Times New Roman;margin:0;text-indent:36pt;text-align:justify"> </p> <p style="font:11pt Times New Roman;margin:0;text-align:justify">The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amount of revenues and expenses during the reporting period. Actual results could differ from those estimates. </p>
CY2022Q4	fil	Inventory Allowances InventoryAllowances	1914891	usd
CY2021Q4	fil	Inventory Allowances InventoryAllowances	1914891	usd
CY2022Q4	us-gaap	Inventory Raw Materials InventoryRawMaterials	1483764	usd
CY2021Q4	us-gaap	Inventory Raw Materials InventoryRawMaterials	1757808	usd
CY2022Q4	us-gaap	Inventory Finished Goods InventoryFinishedGoods	310600	usd
CY2021Q4	us-gaap	Inventory Finished Goods InventoryFinishedGoods	194490	usd
CY2022Q4	us-gaap	Inventory Work In Process InventoryWorkInProcess	24764	usd
CY2021Q4	us-gaap	Inventory Work In Process InventoryWorkInProcess	5668	usd
CY2022Q4	us-gaap	Inventory Net InventoryNet	1819128	usd
CY2021Q4	us-gaap	Inventory Net InventoryNet	1957966	usd
CY2022	us-gaap	Concentration Risk Credit Risk ConcentrationRiskCreditRisk	<p style="font:11pt Times New Roman;margin:0;text-align:justify"><b><i>Concentration</i></b></p> <p style="font:11pt Times New Roman;margin:0;text-align:justify"> </p> <p style="font:11pt Times New Roman;margin:0;color:#000000;text-align:justify">There is no concentration of revenue for the months ended December 31, 2021 and for the months ended December 31, 2022<span style="background-color:#FFFFFF"> because the revenue was earned from multiple customers.</span></p>
CY2022Q4	us-gaap	Operating Loss Carryforwards OperatingLossCarryforwards	15926742	usd
CY2021Q4	us-gaap	Derivative Liabilities DerivativeLiabilities	92527	usd
CY2022	fil	Convertible Debt Issued ConvertibleDebtIssued	297807	usd
CY2022	fil	Convertible Debt Change In Fair Value Recognized In Operations ConvertibleDebtChangeInFairValueRecognizedInOperations	-203822	usd
CY2022	fil	Convertible Debt Converted ConvertibleDebtConverted	-84501	usd
CY2022Q4	us-gaap	Derivative Liabilities DerivativeLiabilities	102011	usd
CY2022Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-15926742	usd
CY2022Q4	us-gaap	Salaries Wages And Officers Compensation SalariesWagesAndOfficersCompensation	1000	usd
CY2021Q4	us-gaap	Salaries Wages And Officers Compensation SalariesWagesAndOfficersCompensation	65000	usd
CY2022Q4	us-gaap	Operating Leases Future Minimum Payments Due Current OperatingLeasesFutureMinimumPaymentsDueCurrent	68042	usd
CY2022Q4	us-gaap	Operating Leases Future Minimum Payments Due In Two Years OperatingLeasesFutureMinimumPaymentsDueInTwoYears	70883	usd
CY2022Q4	us-gaap	Operating Leases Future Minimum Payments Due In Three Years OperatingLeasesFutureMinimumPaymentsDueInThreeYears	5926	usd
CY2022Q4	us-gaap	Operating Leases Future Minimum Payments Due OperatingLeasesFutureMinimumPaymentsDue	144851	usd
CY2022	us-gaap	Lease And Rental Expense LeaseAndRentalExpense	63745	usd
CY2021	us-gaap	Lease And Rental Expense LeaseAndRentalExpense	55440	usd
CY2022Q4	fil	Due To Related Parties DueToRelatedParties	276236	usd
CY2022Q4	us-gaap	Interest Payable Current And Noncurrent InterestPayableCurrentAndNoncurrent	2713	usd
CY2022Q4	us-gaap	Convertible Debt ConvertibleDebt	317285	usd
CY2022Q4	us-gaap	Debt Instrument Unamortized Discount DebtInstrumentUnamortizedDiscount	0	usd
CY2022Q4	us-gaap	Convertible Notes Payable ConvertibleNotesPayable	317285	usd
CY2022Q4	fil	Convertible Debt Accrued Interest ConvertibleDebtAccruedInterest	18674	usd
CY2017Q1	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	75000000	shares
CY2021Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2022Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2017Q1	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	500000000	shares
CY2021Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	75000000	shares
CY2022Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	75000000	shares
CY2018Q1	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	1000000000	shares
CY2022Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	2500000000	shares
CY2021Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	2500000000	shares
CY2018Q2	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	2500000000	shares
CY2022	us-gaap	Stockholders Equity Reverse Stock Split StockholdersEquityReverseStockSplit	The Company effectuated a reverse stock split of 1-for-250 as of July 23, 2018
CY2022Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2021	fil	Warrants Issued WarrantsIssued	14000000	shares
CY2022	fil	Warrants Outstanding WarrantsOutstanding	16000000	shares
CY2022	fil	Warrants Fully Vested WarrantsFullyVested	16000000	shares
CY2021	fil	Issuance Of Common Stock Omnibus Stock Grant And Option Plan IssuanceOfCommonStockOmnibusStockGrantAndOptionPlan	7500000	shares

Files In Submission

Name	View Source	Status
0001096906-23-000699-index-headers.html	Edgar Link	pending
0001096906-23-000699-index.html	Edgar Link	pending
0001096906-23-000699.txt	Edgar Link	pending
0001096906-23-000699-xbrl.zip	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
hyex-20221231.htm	Edgar Link	pending
hyex-20221231.xsd	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
hyex-20221231_cal.xml	Edgar Link	unprocessable
hyex10k_1.jpg	Edgar Link	pending
hyex10k_2.jpg	Edgar Link	pending
hyex10k_3.jpg	Edgar Link	pending
hyex10k_4.jpg	Edgar Link	pending
hyex10k_5.jpg	Edgar Link	pending
hyex10k_6.jpg	Edgar Link	pending
hyex10k_7.jpg	Edgar Link	pending
hyexex10z8_1.jpg	Edgar Link	pending
hyex_ex10z8.htm	Edgar Link	pending
hyex_ex31z1.htm	Edgar Link	pending
hyex_ex31z2.htm	Edgar Link	pending
hyex_ex32z1.htm	Edgar Link	pending
hyex_ex32z2.htm	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
hyex-20221231_pre.xml	Edgar Link	unprocessable
hyex-20221231_htm.xml	Edgar Link	completed
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
hyex-20221231_def.xml	Edgar Link	unprocessable
hyex-20221231_lab.xml	Edgar Link	unprocessable

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$HYEX
HEALTHY EXTRACTS INC. Stock $hyex

2023 Q1 Form 10-K Financial Statement

#000109690623000699 Filed on March 31, 2023

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$HYEX HEALTHY EXTRACTS INC. Stock $hyex

2023 Q1 Form 10-K Financial Statement

#000109690623000699 Filed on March 31, 2023

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$HYEX
HEALTHY EXTRACTS INC. Stock $hyex